These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 11758572

  • 1. Overview of the Hatch-Waxman Act and its impact on the drug development process.
    Mossinghoff GJ.
    Food Drug Law J; 1999; 54(2):187-94. PubMed ID: 11758572
    [No Abstract] [Full Text] [Related]

  • 2. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC.
    Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
    [No Abstract] [Full Text] [Related]

  • 3. Sublicense or supply agreement? Supreme Court of Canada interpretation benefits generic pharmaceutical industry.
    Burshtein S.
    Food Drug Law J; 1999; 54(1):73-91. PubMed ID: 11758562
    [No Abstract] [Full Text] [Related]

  • 4. Navigating the Hatch-Waxman Act's safe harbor.
    Jones PB.
    Food Drug Law J; 2002; 57(3):475-89. PubMed ID: 12710407
    [No Abstract] [Full Text] [Related]

  • 5. The ongoing regulation of generic drugs.
    Frank RG.
    N Engl J Med; 2007 Nov 15; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract] [Full Text] [Related]

  • 6. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers.
    Rea TS.
    Food Drug Law J; 1999 Nov 15; 54(2):223-5. PubMed ID: 11759713
    [No Abstract] [Full Text] [Related]

  • 7. Protecting the balance of Hatch-Waxman: understanding the industry's new dynamics for the 21st century.
    Schroeder RG, Papas P.
    Food Drug Law J; 2001 Nov 15; 56(1):19-26. PubMed ID: 11942348
    [No Abstract] [Full Text] [Related]

  • 8. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond.
    Kelly C.
    Food Drug Law J; 2011 Nov 15; 66(3):417-78, iii. PubMed ID: 24505856
    [Abstract] [Full Text] [Related]

  • 9. The Hatch-Waxman Act during patent prosecution and beyond.
    Mahn TG.
    Food Drug Law J; 1999 Nov 15; 54(2):233-6. PubMed ID: 11758578
    [No Abstract] [Full Text] [Related]

  • 10. FDA's role in administering the Hatch-Waxman Act.
    Malkin BJ.
    Food Drug Law J; 1999 Nov 15; 54(2):211-4. PubMed ID: 11758575
    [No Abstract] [Full Text] [Related]

  • 11. Patenting drug products: anticipating Hatch-Waxman issues during the claims drafting process.
    Mahn TG.
    Food Drug Law J; 1999 Nov 15; 54(2):245-53. PubMed ID: 11758582
    [No Abstract] [Full Text] [Related]

  • 12. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H.
    Food Drug Law J; 2003 Nov 15; 58(1):51-80. PubMed ID: 12739584
    [No Abstract] [Full Text] [Related]

  • 13. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Lewis RA.
    J Contemp Health Law Policy; 1992 Nov 15; 8():361-78. PubMed ID: 10118987
    [No Abstract] [Full Text] [Related]

  • 14. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR.
    Suffolk Univ Law Rev; 2003 Nov 15; 36(3):787-819. PubMed ID: 16493844
    [No Abstract] [Full Text] [Related]

  • 15. Patents: a threat to innovation?
    Manocaran M.
    Science; 2010 Jan 01; 327(5961):31-2; author reply 32. PubMed ID: 20044557
    [No Abstract] [Full Text] [Related]

  • 16. Using market-exclusivity incentives to promote pharmaceutical innovation.
    Kesselheim AS.
    N Engl J Med; 2010 Nov 04; 363(19):1855-62. PubMed ID: 21047231
    [No Abstract] [Full Text] [Related]

  • 17. A generic problem.
    Hanauer SB.
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec 04; 3(12):649. PubMed ID: 17130869
    [No Abstract] [Full Text] [Related]

  • 18. Fifty years of drug amendments revisited: in easy-to-swallow capsule form.
    Kaplan AH.
    Food Drug Law J; 1995 Dec 04; 50 Spec():179-96. PubMed ID: 10343042
    [No Abstract] [Full Text] [Related]

  • 19. Pharmaceutical patent life-cycle management after KSR v. Teleflex.
    Furrow ME.
    Food Drug Law J; 2008 Dec 04; 63(1):275-320. PubMed ID: 18561462
    [No Abstract] [Full Text] [Related]

  • 20. A shift on "pay for delay"--reopening doors for pharmaceutical competition?
    Hemphill Kraus EJ.
    N Engl J Med; 2012 Nov 01; 367(18):1681-3. PubMed ID: 23113478
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.